Find policies, billing codes, payers, states, and providers
Pancreaticoduodenectomy (Whipple Resection)
Customize your policy alerts
Sign up for Aetna Policy 0365 alerts
Get alerted when Policy 0365 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage guidance for pancreaticoduodenectomy (Whipple resection) including indications considered medically necessary, interventions considered experimental/investigational, and associated coding for Aetna members and providers.
No material clinical or coverage changes in this revision.
Coverage Criteria for Pancreaticoduodenectomy (Whipple)
Medically Necessary Indications
Aetna considers the following interventions medically necessary:
Documentation should support one of these indications and appropriate diagnosis coding.
Experimental and Investigational
Aetna considers the following experimental and investigational (not covered):
Effectiveness not established per policy.
Procedure Components
Intervention evidence summaries
Summaries of findings — not explicit coverage rules in these excerpts. Use evidence to inform coverage decisions as below.
See randomized trial and Cochrane review summaries.
See Cochrane and meta-analysis summaries.
See cohort studies and IPOD RCT.
Relaparotomy management
Evidence-based preference when relaparotomy for pancreatic fistula is required
Based on retrospective multicenter cohort and systematic review/meta-analysis evidence.
PPH prophylaxis
Preventive technique for post-pancreatectomy hemorrhage (PPH)
Consider during pancreatoduodenectomy to potentially reduce PPH from hepatic or gastro-duodenal artery stump.
Surgical approach considerations
Comparative outcomes by surgical approach
Apply caution during surgeon learning curve; reserve MIS approaches for experienced centers or selected patients.
Evidence summary
Summary of evidence comparing minimally invasive (LPD/robotic) versus open PD and adjunctive vessel wrapping:
Supported by multicenter RCTs and large meta-analyses; see vessel wrapping evidence separately.
Regional vessel wrapping
Adjunctive technique to reduce post-operative hemorrhage:
Wrapping materials included omentum, falciform ligament, or ligamentum teres.
The policy explicitly lists ICD-10 code E16.4 (Zollinger‑Ellison syndrome) among diagnosis codes that are not covered for the indications described in this Clinical Policy Bulletin. Pancreaticoduodenectomy for Zollinger‑Ellison syndrome is also identified in the policy text as an experimental and investigational indication and therefore considered not medically necessary for that condition.
A meta‑analysis and the policy statement indicate that routine preoperative biliary drainage (PBD) before pancreaticoduodenectomy is not recommended. PBD was associated with increased post‑operative infectious complications, wound infection, and delayed gastric emptying; the authors concluded PBD probably should not be routinely carried out in patients undergoing PD.
The provided document excerpts do not list additional explicit procedural exclusions beyond those called out elsewhere (for example, Zollinger‑Ellison syndrome and certain adjuncts). Where evidence is uncertain (such as fibrin sealant patches), the text summarizes trial results but does not state a blanket exclusion in these specific chunks.
The policy lists accepted indications for pancreatic head resection—including pancreatic adenocarcinoma, ampullary carcinoma/adenoma, neuroendocrine tumors, cholangiocarcinoma, duodenal neoplasm, combined pancreatic/duodenal injury, and chronic pancreatitis—but these excerpts do not provide explicit exclusions that would prohibit PD when those indications are present.
Minimally invasive pancreaticoduodenectomy (laparoscopic or robotic) is described as technically feasible but also as a complex operation suited only to selected patients. Outcomes are largely comparable to open PD when performed in experienced, high‑volume centers, but the evidence is limited and influenced by learning‑curve effects.
Pancreaticoduodenectomy performed for Zollinger‑Ellison syndrome is identified in the policy as experimental and investigational. Accordingly, PD for ZES is considered not medically necessary under this CPB, and medical therapy (proton‑pump inhibitors) remains the standard initial treatment approach.
Randomized trials and systematic reviews summarized in the policy do not support routine use of fibrin sealant patches or routine gastric decompression to prevent or reduce clinically significant post‑operative pancreatic fistula. The available studies showed little or no consistent benefit in POPF rates, mortality, overall morbidity, re‑operation rate, or length of stay.
Within the provided excerpts there are no explicit statements phrased as general 'not medically necessary' declarations beyond the experimental/investigational items already identified (e.g., PD for Zollinger‑Ellison syndrome, preoperative biliary drainage for prevention of complications, omental flap). Other interventions are discussed with equivocal or limited evidence but are not uniformly labeled 'not medically necessary' in these chunks.
An UpToDate review and the summarized evidence note that robotic‑assisted pancreaticoduodenectomy has not reduced perioperative morbidity or mortality. Laparoscopic PD can yield comparable outcomes in experienced centers but is complex and suitable only for selected patients; high‑quality randomized data remain limited.
Coding and Billing for Pancreaticoduodenectomy
| 48150 | Pancreatectomy, proximal subtotal with total duodenectomy, partial gastrectomy, choledochoenterostomy and gastrojejunostomy (Whipple-type procedure); with pancreatojejunostomy. |
| 48152 | Pancreatectomy, proximal subtotal... without pancreatojejunostomy. |
| 48153 | Pancreatectomy, proximal subtotal with near-total duodenectomy, choledochoenterostomy and duodenojejunostomy (pylorus-sparing, Whipple-type procedure); with pancreatojejunostomy. |
| 48154 | Pancreatectomy, proximal subtotal... without pancreatojejunostomy. |
| 49905 | Omental flap, intra-abdominal (List separately in addition to code for primary procedure). |
| 47533 | Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; external [not covered for prevention of complications]. |
| 47534 | Placement of biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, ultrasound and/or fluoroscopy), and all associated radiological supervision and interpretation; internal-external [not covered for prevention of complications]. |
| 47535 | Conversion of external biliary drainage catheter to internal-external biliary drainage catheter, percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation [not covered for prevention of complications]. |
| 47536 | Exchange of biliary drainage catheter (eg, external, internal-external, or conversion of internal-external to external only), percutaneous, including diagnostic cholangiography when performed, imaging guidance (eg, fluoroscopy), and all associated radiological supervision and interpretation [not covered for prevention of complications]. |
| 44130 | Enteroenterostomy, anastomosis of intestine, with or without cutaneous enterostomy (separate procedure) [Braun enteroenterostomy]. |
| C17.0 | Malignant neoplasm of duodenum. |
| C22.1 | Intrahepatic bile duct carcinoma. |
| C24.0 | Malignant neoplasm of extrahepatic bile duct. |
| C24.1 | Malignant neoplasm of ampulla of Vater. |
| C25.0-C25.9 | Malignant neoplasm of pancreas. |
| C7A.00-C7B.8 | Neuroendocrine tumors. |
| D01.49 | Carcinoma in situ of other parts of intestine. |
| D13.6 | Benign neoplasm of pancreas. |
| K86.0 | Alcohol-induced chronic pancreatitis. |
| E16.4 | Increased secretion of gastrin [Zollinger-Ellison syndrome]. |
| Fibrin sealant - no specific code; considered integral to pancreaticoduodenectomy and not separately reimbursed. |
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Provider action: None specified
None specified in the provided excerpts.
Authorization / Billing — no explicit authorization requirements stated
No explicit prior authorization or billing denials are stated in these sections. The CPT codes for pancreaticoduodenectomy (e.g., 48150, 48152, 48153, 48154) and Braun enteroenterostomy (44130) are listed as covered when selection criteria are met; omental flap (49905) and preoperative biliary drainage codes (47533, 47534, 47535) are noted as not covered for prevention of complications. Providers should verify coverage with the payer for individual cases.
Provider action: No explicit authorization or billing requirements
No explicit prior authorization or billing requirements are described in the provided excerpts. Treating providers should confirm any payer-specific authorization requirements prior to scheduling.
Documentation — Risk factor stratification documented in RCTs
Randomized trial(s) and stratified analyses documented risk-factor stratification by gland texture, pancreatic duct size, obesity, and neoadjuvant treatment when assessing interventions (e.g., fibrin sealant patch trial stratified by gland texture, duct size, and neoadjuvant therapy). Providers should document these risk factors in the record when relevant.
- Risk factors identified as significant for POPF: obesity, soft gland texture, small duct size
- Trials stratified by: gland texture, pancreatic duct size, neoadjuvant therapy
Step therapy / sequencing
Step therapy / sequencing: No formal step therapy policy is stated. Clinical sequencing noted in background: for Zollinger-Ellison syndrome medical therapy with proton pump inhibitors (PPIs) is standard first-line; surgery (including tumor resection) may be considered when appropriate. For other perioperative strategies, evidence supports selective use (e.g., external vs internal pancreatic duct stents) and further RCTs are needed.
- Zollinger-Ellison syndrome: medical therapy (PPIs) is standard before considering surgery
- Pancreatic duct stents: evidence on external vs internal stents is limited; more RCTs needed
- No formal step therapy or mandated sequencing in these excerpts
Surgical approach preference for relaparotomy
When relaparotomy is required for pancreatic fistula after pancreatoduodenectomy, evidence indicates higher mortality with completion pancreatectomy compared with pancreas-preserving procedures; pancreas-preserving approaches are generally preferred when feasible and should be documented.
- Completion pancreatectomy associated with higher mortality versus pancreas-preserving procedures (adjusted OR 2.55)
- Document rationale for choice of relaparotomy procedure in the chart
Consider center/surgeon volume for MIPD
Consideration of center and surgeon volume is advised for minimally invasive pancreaticoduodenectomy (MIPD). Current evidence suggests MIPD may have acceptable outcomes when performed at experienced, high-volume centers; registry participation, training, and selective use are recommended.
- MIPD outcomes comparable in selected patients when performed at experienced, high-volume centers
- Registry participation and prospective evaluation encouraged
- Be cautious introducing MIPD during the early learning curve (consider hybrid approaches)
Denial risk — experimental / investigational indications
Denial triggers: procedures performed for experimental or investigational indications (e.g., pancreaticoduodenectomy for Zollinger-Ellison syndrome) may be considered not medically necessary and subject to denial. Providers should document indications that align with the CPB's listed medically necessary indications.
- Zollinger-Ellison syndrome: PD is considered experimental/investigational by Aetna
- Ensure documentation supports one of the listed medically necessary indications (e.g., pancreatic adenocarcinoma, ampullary carcinoma, chronic pancreatitis, etc.)
Required clinical outcome documentation
Required clinical outcome documentation: trials and series commonly report outcomes such as post-operative pancreatic fistula (POPF), mortality, overall morbidity, reoperation, readmission, and length of stay. Providers should include these outcomes in operative and post-operative documentation as appropriate.
- Document POPF grade, mortality, morbidity, reoperation/readmission, and hospital length of stay (LOS)
Preoperative biliary drainage — increased complication risk
Preoperative biliary drainage (PBD) is associated with increased infectious complications, wound infection, and delayed gastric emptying in pooled analyses; PBD should not be routinely performed before pancreaticoduodenectomy and use should be justified and documented.
- Meta-analysis showed increased risk with PBD: infectious complications (OR 1.52), wound infection (OR 2.09), and DGE (OR 1.37)
- Document indication and justification when PBD is performed
Notice about CPB scope and verification
Clinical Policy Bulletin (CPB) scope notice: CPBs assist in administering plan benefits and do not constitute guarantees of coverage. Providers must verify member-specific benefits and eligibility prior to treatment.
- CPB is informational and not a contract or coverage guarantee
- Participating providers should verify member coverage and authorization requirements
Background and Rationale
Pancreaticoduodenectomy (Whipple resection) is a major operation that removes the pancreatic head with duodenectomy and reconstruction. It is used primarily for malignancies and selected benign lesions of the pancreatic head and periampullary region. Indications listed in the policy include pancreatic adenocarcinoma, IPMN with high‑grade dysplasia or invasive cancer, ampullary and bile duct cancers, chronic pancreatitis, duodenal neoplasms, neuroendocrine tumors, and selected traumatic injuries; the policy also notes that the role of PD for Zollinger‑Ellison syndrome is controversial and considered investigational.
Definitions and Abbreviations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.